← FDA DRUG APPROVALS

FDA NDA · NDA021754

MYCAMINE

Sponsor: FUJISAWA HLTHCARE

APPLICATION
NDA021754
TYPE
NDA
ORIGINAL APPROVAL
2005-03-16
LATEST ACTION
2005-03-16
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

MYCAMINEPrescription
MICAFUNGIN SODIUM 50MG · INJECTABLE · INJECTION

Approval history

2005-03-16Type 6 - New Indication (no longer used) · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →